NASDAQ:NXTC NextCure (NXTC) Stock Price, News & Analysis → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Free NXTC Stock Alerts $1.39 +0.16 (+13.01%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$1.24▼$1.4450-Day Range$1.17▼$2.4952-Week Range$0.98▼$2.57Volume55,120 shsAverage Volume83,402 shsMarket Capitalization$38.88 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get NextCure alerts: Email Address NextCure MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside331.7% Upside$6.00 Price TargetShort InterestHealthy0.43% of Float Sold ShortDividend StrengthN/ASustainability-0.79Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.71) to ($1.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.70 out of 5 starsMedical Sector219th out of 903 stocksPharmaceutical Preparations Industry98th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingNextCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNextCure has only been the subject of 2 research reports in the past 90 days.Read more about NextCure's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.43% of the float of NextCure has been sold short.Short Interest Ratio / Days to CoverNextCure has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NextCure has recently decreased by 19.48%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNextCure does not currently pay a dividend.Dividend GrowthNextCure does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNextCure has received a 71.38% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for NextCure is -0.79. Previous Next N/A News and Social Media Coverage Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NextCure insiders have not sold or bought any company stock.Percentage Held by Insiders13.30% of the stock of NextCure is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.65% of the stock of NextCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NextCure's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for NextCure are expected to grow in the coming year, from ($1.71) to ($1.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NextCure is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NextCure is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNextCure has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about NextCure's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wealthpin ProTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. About NextCure Stock (NASDAQ:NXTC)NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.Read More NXTC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NXTC Stock News HeadlinesJune 1, 2024 | americanbankingnews.comNextCure (NASDAQ:NXTC) Earns Buy Rating from HC WainwrightMay 30, 2024 | globenewswire.comNextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024May 29, 2024 | finance.yahoo.comNextCure, Inc. (NXTC)May 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for NextCure Amid Promising Oncology Treatment Prospects and Solid FinancialsMay 2, 2024 | investorplace.comNXTC Stock Earnings: NextCure Misses EPS for Q1 2024May 2, 2024 | globenewswire.comNextCure Provides Business Update and Reports First Quarter 2024 Financial ResultsApril 24, 2024 | globenewswire.comNextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024April 8, 2024 | markets.businessinsider.comPromising Clinical Outlook for NextCure’s Novel ADC LNCB74 Spurs Buy RatingApril 8, 2024 | globenewswire.comNextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024April 4, 2024 | globenewswire.comNextCure Appoints Dr. Rakesh Dixit to Scientific Advisory BoardApril 2, 2024 | globenewswire.comNextCure to Present at 23rd Annual Needham Virtual Healthcare ConferenceMarch 27, 2024 | finance.yahoo.comWill NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?March 23, 2024 | investorplace.comWall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy RichMarch 22, 2024 | markets.businessinsider.comPromising Clinical Trial Results for NextCure’s NC410 Bolster Buy RatingMarch 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Femasys (FEMY) and NextCure (NXTC)March 21, 2024 | marketwatch.comNextCure to Cut 37% of Jobs, Will Narrow Focus on Drug CandidatesMarch 21, 2024 | bizjournals.comMd. biopharma lays off staff, pauses manufacturing to preserve cashMarch 21, 2024 | globenewswire.comNextCure Provides Business Update and Reports Full Year 2023 Financial ResultsMarch 5, 2024 | globenewswire.comNextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science AdvancesJanuary 18, 2024 | finance.yahoo.comNextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway DisordersDecember 28, 2023 | benzinga.comNextCure Stock (NASDAQ:NXTC) Dividends: History, Yield and DatesDecember 25, 2023 | finance.yahoo.comHere's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom FishingDecember 21, 2023 | finance.yahoo.comNextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord InjuryDecember 15, 2023 | finance.yahoo.comNextCure (NXTC) Down on Shelving Plans to Develop CandidateDecember 15, 2023 | markets.businessinsider.comBuy Rating Justified by NextCure’s Promising Developments in MSS-CRC Treatment and Strategic Pipeline ShiftSee More Headlines Receive NXTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today6/09/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NXTC CUSIPN/A CIK1661059 Webwww.nextcure.com Phone(240) 399-4900FaxN/AEmployees82Year Founded2015Price Target and Rating Average Stock Price Target$6.00 High Stock Price Target$8.00 Low Stock Price Target$4.00 Potential Upside/Downside+331.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,720,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.29% Return on Assets-47.52% Debt Debt-to-Equity RatioN/A Current Ratio10.70 Quick Ratio10.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.10 per share Price / Book0.34Miscellaneous Outstanding Shares27,970,000Free Float24,253,000Market Cap$38.88 million OptionableOptionable Beta0.60 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Michael S. Richman MSBA (Age 63)Co-Founder, CEO, President & Director Comp: $698.39kDr. Solomon Langermann Ph.D. (Age 64)Chief Scientific Officer Comp: $530.32kDr. Han Myint FACP (Age 70)M.D., Chief Medical Officer Comp: $546.66kDr. Lieping Chen M.D. (Age 67)Ph.D., Co-Founder & Chairman of Scientific Advisory Board Mr. Steven P. Cobourn CPA (Age 61)Chief Financial Officer Comp: $313.25kDr. Timothy Mayer Ph.D. (Age 59)Chief Operating Officer Mr. Kevin G. Shaw (Age 49)Senior VP & General Counsel Ms. Stacy RollingerVice President of Human ResourcesMr. Sourav Kundu Ph.D. (Age 63)Senior Vice President of Development & Manufacturing Dr. Sebastien MalovesteSenior Vice President of Business DevelopmentMore ExecutivesKey CompetitorsKezar Life SciencesNASDAQ:KZRHookipa PharmaNASDAQ:HOOKParatek PharmaceuticalsNASDAQ:PRTKRepare TherapeuticsNASDAQ:RPTXVeruNASDAQ:VERUView All CompetitorsInstitutional OwnershipAffinity Asset Advisors LLCBought 1,359,037 shares on 5/15/2024Ownership: 4.859%Vanguard Group Inc.Bought 83,700 shares on 5/10/2024Ownership: 3.530%Assenagon Asset Management S.A.Bought 426,717 shares on 4/24/2024Ownership: 1.529%View All Institutional Transactions NXTC Stock Analysis - Frequently Asked Questions Should I buy or sell NextCure stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NXTC shares. View NXTC analyst ratings or view top-rated stocks. What is NextCure's stock price target for 2024? 2 brokers have issued 12 month price objectives for NextCure's shares. Their NXTC share price targets range from $4.00 to $8.00. On average, they expect the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 331.7% from the stock's current price. View analysts price targets for NXTC or view top-rated stocks among Wall Street analysts. How have NXTC shares performed in 2024? NextCure's stock was trading at $1.14 at the beginning of 2024. Since then, NXTC stock has increased by 21.9% and is now trading at $1.39. View the best growth stocks for 2024 here. Are investors shorting NextCure? NextCure saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 90,500 shares, a drop of 19.5% from the April 30th total of 112,400 shares. Based on an average trading volume of 287,500 shares, the short-interest ratio is presently 0.3 days. Currently, 0.4% of the company's stock are short sold. View NextCure's Short Interest. When is NextCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our NXTC earnings forecast. How were NextCure's earnings last quarter? NextCure, Inc. (NASDAQ:NXTC) posted its quarterly earnings results on Thursday, May, 2nd. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.45) by $0.16. What other stocks do shareholders of NextCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include SCYNEXIS (SCYX), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Novan (NOVN), Organigram (OGI), Kadmon (KDMN), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and DHT (DHT). When did NextCure IPO? NextCure (NXTC) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO. Who are NextCure's major shareholders? NextCure's stock is owned by a number of retail and institutional investors. Top institutional investors include Affinity Asset Advisors LLC (4.86%), Vanguard Group Inc. (3.53%) and Assenagon Asset Management S.A. (1.53%). View institutional ownership trends. How do I buy shares of NextCure? Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NXTC) was last updated on 6/9/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
